Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2012558-47-1
Molecular formula
C248H355N65O72
Molecular weight
5399 g/mol
Drug class
Hepatitis D virus (HDV) entry inhibitormyristoylated pre-S1 lipopeptide
Mechanism of action
Binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, blocking entry of hepatitis B and D viruses into liver cells. It prevents new infection of hepatocytes but does not directly eliminate intracellular viral genomes.
Indications / reported uses
Treatment of chronic hepatitis D virus (HDV) infection in adults with compensated liver disease, with or without concomitant HBV infection, under the EU-authorised Hepcludex indication; use in combination with HBV management as directed by specialist product information
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Bulevirtide Environmental Risk Assessment (ERA) (the Bulevirtide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.